Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04663282 · ClinicalTrials.gov registry record · Phase 2
A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics
A Phase 2 study of Type 2 Diabetes, sponsored by Jiangsu HengRui Medicine Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 179
- Enrollment target
- 20
- Study locations
NCT04663282: Completed Phase 2 study of Type 2 Diabetes, sponsored by Jiangsu HengRui Medicine Co..
NCT04663282 is a Phase 2 study of Type 2 Diabetes that has completed, run by Jiangsu HengRui Medicine Co.. The registered enrollment target is 179 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04663282, a Phase 2 study of Type 2 Diabetes, has completed, sponsored by Jiangsu HengRui Medicine Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 179 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is being conducted to evaluate the efficacy and safety of IND068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with one or two oral antidiabetics compared to insulin degludec QD for 16 weeks.
Primary Outcome
Change from baseline in Glycosylated Haemoglobin after 16 weeks of treatment
Conditions Studied
Interventions
- DRUG Insulin Degludec
- DRUG INS068 injection
Study Locations (20)
California
- National Research Institute - Huntington Park - Huntington Park
- Clinical Trials Research - Lincoln
- Torrance Clinical Research Institute Inc - Lomita
- National Research Institute - Wilshire - Los Angeles
Florida
- ALL Medical Research, LLC - Cooper City
- New Generation of Medical Research - Hialeah
- Clinical Pharmacology of Miami, LLC - Miami
- Progressive Medical Research - Port Orange
Texas
- Juno Research, LL - Houston
- Juno Research, LLC - Medical Center Office - Houston
- Juno Research, LLC - Southwest Houston Site - Houston
- Endeavor Clinical Trials - San Antonio
Ohio
- Endocrinology Associates, Inc - Columbus
- Prestige Clinical Research - Franklin
Victoria
- The Royal Melbourne Hospital - Melbourne
- Austin Health (Heidelberg Repatriation Hospital) - Melbourne
Iowa
- Iowa Diabetes and Endocrinology Research Center - West Des Moines
Queensland
- Core Research Group Pty Ltd - Brisbane
Beijing Municipality
- Peking University People's Hospital - Beijing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2021-02-04 |
| Est. Completion | 2022-05-28 |
| Phase | Phase 2 |
What the finished NCT04663282 record still lists
NCT04663282 is an interventional study that assigns participants to a tested intervention. The registered 179 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Insulin Degludec is the first listed.
NCT04663282 names 20 study sites across 9 states, led by California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT04663282 about?
NCT04663282 is a clinical study titled "A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics". The study is being conducted to evaluate the efficacy and safety of IND068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with one or two oral antidiabetics compared to insulin degludec QD for 16 weeks.
What is the current status of trial NCT04663282?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2021-02-04. Estimated completion is 2022-05-28.
What conditions does trial NCT04663282 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT04663282?
The interventions under investigation include: Insulin Degludec (DRUG), INS068 injection (DRUG).
Who is sponsoring clinical trial NCT04663282?
This trial is sponsored by Jiangsu HengRui Medicine Co., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04663282 being conducted?
This trial has 20 study locations across California, Florida, Iowa, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04663282's enrollment target sits among peer trials
179 107th of 327 higher than 221 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Renal Mechanism of SGLT2 Inhibition
RECRUITING · Phase 2
-
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
RECRUITING · Phase 2
-
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
RECRUITING · Phase 2
-
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
RECRUITING · Phase 2
-
NAD Augmentation in Diabetes Kidney Disease
RECRUITING · Phase 2
-
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06581198 · 179 participants · Phase 2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
- NCT07356323 · 179 participants · NA
A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic Surgery
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI